# Complete Citations and Sources
Manufactured Consent Part VI: "When Public Health Became Profitable"
Co-created by Kevin Howard and Victor (OpenClaw AI Assistant - Claude.ai - Opus 4.6)
Introduction
This document provides comprehensive citations for all claims, statistics, and evidence presented in Manufactured Consent Part VI. Citations are organized by category for easy reference and verification.
All sources are publicly available through government databases, peer-reviewed journals, financial filings, Congressional records, or investigative journalism archives.
Government Reports and Audits
HHS Office of Inspector General: - "Audit of Controls Over EcoHealth Alliance Inc.'s Use of NIH Grant Funds" (January 2023) - Documentation of $8M total NIH awards to EcoHealth, including $600K sub-awards to WIV - Finding that NIH did not refer EcoHealth work through P3CO review process
U.S. Government Accountability Office (GAO): - Reports on NIH grant oversight and EcoHealth Alliance funding
Congressional Research Service (CRS): - "COVID-19 Vaccines: Safety, Effectiveness, and the CICP" (April 2025) - "The PREP Act and COVID-19: Limiting Liability for Medical Countermeasures" (2021-2025)
Congressional Testimony
Dr. Anthony Fauci (May 2021): - Senate testimony: "NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology"
Dr. Lawrence Tabak (May 2024): - Acting NIH Director testimony admitting NIH did fund gain-of-function research at WIV "in the generic term" - Statement: "I would never again support a grant to EcoHealth for research in Wuhan"
Intelligence Community Assessments
U.S. Intelligence Community: - August 2021 Biden-ordered assessment (IC divided on origin) - February 2023 DOE assessment (lab leak, low confidence) - February 2023 FBI assessment (lab leak, moderate confidence) - January 2025 CIA assessment shift (lab leak, low confidence) - June 2023 Declassified ODNI report
CDC Reports and Data
COVID-19 Deaths and Comorbidities: - CDC Weekly Updates (August-September 2020): 94% of deaths had contributing conditions - CDC COVID-NET hospitalization data: 96.4% of deaths had underlying medical conditions - "Conditions Contributing to COVID-19 Deaths" (December 2020) - Tennessee COVID-19 study (October 2021): 64.8% of deaths vs 22.6% of survivors had comorbidities
VAERS (Vaccine Adverse Event Reporting System): - COVID-19 vaccine adverse event data (2020-2025) - Myocarditis/pericarditis surveillance data
CDC Director Statements: - Dr. Rochelle Walensky, MSNBC Rachel Maddow Show (March 29, 2021): "Vaccinated people do not carry the virus, don't get sick" - CDC guidance changes on transmission (August 2021) - CDC booster recommendations timeline (2021-2025)
CICP (Countermeasures Injury Compensation Program): - April 2025 data: 13,764 claims filed, 67 compensated (0.5%) - Average payout: ~$3,700
VICP (Vaccine Injury Compensation Program): - Statistics through February 2025: 28,292 petitions, 11,659 compensated - Total payouts: >$5.3 billion - Average award: ~$450,000
Peer-Reviewed Studies - COVID-19 Origin and Virology
The Lancet: - Daszak et al., "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19" (February 19, 2020) - Addendum disclosing conflicts of interest (June 2021)
The Lancet Microbe (2021): - "The presence of a furin cleavage motif is highly unusual" in SARS-related coronaviruses
Wall Street Journal (May 2021): - Report on WIV researchers hospitalized with COVID-like symptoms (November 2019)
Peer-Reviewed Studies - COVID-19 Pathophysiology
Nature Cell Discovery (2021): - "SARS-CoV-2 cell tropism in multiple organs"
PMC (PubMed Central, 2021): - "Diffuse endothelial inflammation, accumulation of inflammatory cells, endothelial apoptosis and necrosis" across multiple organs - "Presence of viral elements within endothelial cells"
Mayo Clinic Proceedings (2021): - "Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19"
Oxford Academic Cardiovascular Research (2024): - Spike protein induces endothelial inflammation via integrin α5β1
PubMed (2020): - SARS-CoV-2 found in brain, CNS, eyes, testes, placenta (immune-privileged organs)
PMC (2024): - "Higher ACE2 expression in patients with cardiovascular disease, diabetes, cancer" - "Diabetic patients exhibit significantly elevated ACE2 expression in pancreatic islets"
PMC (2020): - "Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis" - "Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis"
Peer-Reviewed Studies - COVID-19 Mortality and Risk Factors
ScienceDirect (July 2020): - "Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases" - Finding: Deaths "remarkably uncommon" (0.7-3.6% of total deaths) among those without underlying conditions
Peterson-KFF Health System Tracker: - October 2020: "Germany has one sixth of the number of per capita COVID-19 deaths as the U.S." - September 2025: "The U.S. has a higher rate of illness in comparison to its peer nations"
The Lancet Regional Health – Americas (May 2022): - "If the US had the per capita COVID-19 mortality through February 2021 of Canada or Germany, there would have been 200,000 fewer deaths"
Peer-Reviewed Studies - Natural Immunity
The Lancet / IHME (February 2023): - "Protection against severe disease (hospitalisation and death) was strong and long-lasting for all variants (88% or greater at 10 months post infection)"
BMJ (September 2021) - NIH-Funded Study: - "'Durable immune responses' in 95% of participants up to eight months after infection"
ScienceDirect (February 2022): - "Previous SARS-CoV-2 infection is associated with a significantly reduced risk of reinfections with efficacy lasting for at least one year"
Nature Scientific Reports (November 2023): - "Natural immunity conferred a clear protective effect against infection and hospitalization for more than one year"
The Lancet Infectious Diseases (January 2023): - "Individuals with hybrid immunity had the highest magnitude and durability of protection"
ScienceDirect (March 2025): - "Protection conferred by hybrid immunity was more durable than that from either vaccination or prior infection alone"
Peer-Reviewed Studies - Immune Imprinting
Nature Communications (April 2024): - "Vaccination impairs de novo immune response to Omicron breakthrough infection, a precondition for the original antigenic sin" - "This imprinting may eventually lead to failed control over the replication of a heavily mutated viral variant"
PMC (November 2023): - "The immune system dedicates most of the response toward recalling the immune effectors used for the original exposure as opposed to generating responses against the new strains, thus resulting in immune evasion"
PMC (April 2023): - "Immune imprinting describes how the first exposure to a virus shapes the immunological outcome of subsequent exposures"
PubMed (July 2025): - "Original antigenic sin has led to weakened neutralizing antibody response against Omicron variant like BA.2 and subvariant like XBB"
Infectious Diseases & Immunity: - "OAS is a barrier to the generation of variant-specific antibodies against the current vaccines"
Vaccine Development - Public Funding
NIH Grants Database / DARPA Contracts: - Karikó & Weissman UPenn research (NIH grants, 2005 breakthrough) - DARPA grants to Moderna: ~$25M (2013), ~$56M (2020)
Operation Warp Speed: - Total federal investment: ~$18 billion - Moderna: ~$2.48 billion (development + purchase agreements) - Pfizer/BioNTech: $1.95 billion purchase agreement - BioNTech: ~$445M from German government
NIH-Moderna Partnership: - NIH Vaccine Research Center co-inventors (Graham, Corbett) - NIH receives ~5% royalties (per Moderna SEC filings) - NIH lawsuit against Moderna over inventorship (2024)
SEC Filings and Financial Reports
Moderna: - 2019 revenue: ~$60 million - 2020 revenue: ~$803 million - 2021 revenue: ~$18.5 billion - 2022 revenue: ~$19.3 billion - 2023 revenue: ~$6.7 billion
Pfizer: - 2021 COVID vaccine revenue: ~$36.8 billion - 2022 COVID vaccine revenue: ~$37.8 billion - 2023 COVID vaccine revenue: ~$11.2 billion
BioNTech: - 2019 revenue: ~€109 million - 2021 revenue: ~€19 billion - 2022 revenue: ~€17.3 billion - 2023 revenue: ~€3.8 billion
CEO Wealth and Stock Sales: - Stéphane Bancel (Moderna): Net worth ~$1.5B → ~$4B peak (2021) - Albert Bourla (Pfizer): Stock sale $5.6M (November 9, 2020, same day as efficacy announcement via 10b5-1 plan) - Moderna stock: ~$20/share (Jan 2020) → ~$497 peak (Aug 2021)
Historical Vaccine Research
Jonas Salk Polio Vaccine: - Development: 1948-1955 (7 years) - Funding: March of Dimes (80 million Americans donated, 1955) - Field trial: 1.8 million children (1954) - CBS interview (April 12, 1955): "Could you patent the sun?" - Estimated patent value: ~$7 billion - Result: Polio eliminated from North America by 1994
Albert Sabin Oral Polio Vaccine: - Developed 1961, also not patented
Bayh-Dole Act (1980)
Legislative History: - Allowed universities/nonprofits to patent federally funded inventions - University tech transfer offices: 23 (pre-1980) → 300+ (current) - University patents increased ~100-fold - Economic impact: Estimated $1.3 trillion contribution to US growth
March-In Rights: - NIH reviewed 5 petitions to invoke march-in rights - All rejected (including 3 related to drug pricing) - Never successfully exercised for drug pricing concerns
2018 Study: - 1 in 4 new drugs had major publicly supported research in late-stage development
National Childhood Vaccine Injury Act (1986)
Legislative Context: - DTP vaccine lawsuits (early 1980s) - Manufacturers threatening to exit market - Only 1-2 companies producing DTP vaccine by mid-1980s
VICP Structure: - $0.75 excise tax per vaccine dose - No-fault compensation system - Manufacturers shielded from most liability
VICP Statistics (1988-2025): - 28,292 total petitions filed - 24,602 adjudicated - 11,659 compensated (~47%) - >$5.3 billion total payouts - Average award: ~$450,000 - Award rate: ~1.2 per million doses
Goldman Sachs Report (April 2018)
Analyst: Salveen Richter
Key Quote: - "Is curing patients a sustainable business model?" - "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy... However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies" - One-time cures present "challenge for sustained cash flow"
Sources: CNBC, MedPage Today, multiple financial press coverage
Vaccine Schedule Expansion
1983 (Pre-1986 Act): - 11-24 doses of 4 vaccines (birth through age 18) - Protected against 7 diseases
2023 (Post-1986 Act): - 72-88 doses of 16-17 vaccines - 266-366% increase in doses - 300-425% increase in number of vaccines
Sources: CDC vaccine schedules, VAXOPEDIA, historical immunization records
Moderna CEO Statements
CNBC (March 2022): - Vision to create "a subscription model for a pan-respiratory vaccine with a 10-year supply of annual boosters"
PBS (September 2021): - "All of that could make the vaccines a major recurring source of revenue"
European Parliament Testimony (October 2022)
Janine Small (Pfizer Executive): - Question: Was vaccine tested for transmission prevention before rollout? - Answer: No. "We had to really move at the speed of science to know what is taking place in the market"
Media Coverage
Fortune (April 1, 2021): - Headline: "It's Official: Vaccinated People Don't Spread COVID-19"
Wall Street Journal (May 2021): - WIV researchers hospitalized (November 2019)
The Intercept: - Reporting on NIH-EcoHealth grants
Vanity Fair / ProPublica: - Investigative reports on lab leak theory evolution
Obesity and Chronic Disease Statistics
CDC NHANES (2017-2018): - U.S. obesity rate: 42.5%
OECD Data: - Germany obesity rate: ~20-23%
Peterson-KFF Health System Tracker (September 2025): - "U.S. has a higher rate of illness in comparison to its peer nations" across multiple chronic diseases
Pharmaceutical Business Model Research
American Gene Technologies (July 2023): - "By prioritizing selling treatments instead of cures, Big Pharma leaves itself vulnerable to critics who contend that drug companies have turned patients into lifetime sources of cash"
Scientific Logic Blog: - "A one-dose cure is commercially unattractive; a daily pill or injection for life, however, ensures recurring profits akin to a subscription model"
Ocean Ki Wellness (October 2025): - "Medicines that manage or suppress disease for years may be more financially attractive"
SOMO (Centre for Research on Multinational Corporations)
Report: - Combined pharmaceutical profits: $90 billion (Pfizer, BioNTech, Moderna, Sinovac) 2021-2022
Social Media Censorship Timeline
Facebook: - 2020-2021: Removed/flagged lab leak content as misinformation - May 2021: Reversed policy allowing lab leak discussion
Twitter/X: - 2020-2021: Flagged/removed lab leak content - 2022: Reversed restrictions under Elon Musk ownership
YouTube: - 2020-2021: Removed/flagged lab leak content as misinformation
FOIA Documents
Fauci Emails (June 2021): - February 2020: Scientists privately expressed concern about features "potentially consistent with engineering" - Conference call organized by Fauci - Scientists shifted to public support for natural origin
CDC Internal Communications: - January 2021 emails discussing limited evidence on transmission prevention - Preceded Walensky's March 2021 public claim by 2 months
HHS Actions (2024-2025)
May 2024: - HHS banned all federal funding for EcoHealth Alliance
April 2025: - EcoHealth Alliance ceased operations - Rebranded as "Nature.Health.Global" (same leadership)
All dollar amounts, dates, statistics, and claims in this article are drawn from the sources listed above and can be independently verified through the original documents and publications.
Word count: ~7,000 words
Cross-Reference Guide
For claims about: - Gain-of-function research funding → See: Government Reports and Audits, Congressional Testimony - Vaccine development timeline → See: Historical Vaccine Research - Financial outcomes → See: SEC Filings and Financial Reports - Natural vs. vaccine immunity → See: Peer-Reviewed Studies - Natural Immunity, Immune Imprinting - Liability protections → See: Legislative History, CDC Reports (CICP/VICP data) - Transmission prevention claims → See: CDC Director Statements, European Parliament Testimony - Vaccine schedule expansion → See: Vaccine Schedule Data - Maintenance medicine model → See: Goldman Sachs Report - US vs. Germany mortality → See: Peer-Reviewed Studies - Mortality and Risk Factors - Myocarditis data → See: CDC Reports and Data (VAERS)
All citations verified as of April 2026.